Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

Company Overview

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.10 to $1.10
• 50-Day Range: $1.04 to $1.11
• 52-Week Range: $0.59 to $8.08
• Volume: N/A
• Average Volume: 701,788 shs
• Market Capitalization: $36.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Satsuma Pharmaceuticals Stock Analysis - MarketRank™

Satsuma Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat, and ranked 836th out of 912 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Satsuma Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Satsuma Pharmaceuticals are expected to decrease in the coming year, from ($0.82) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Satsuma Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Satsuma Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Satsuma Pharmaceuticals has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for STSA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Satsuma Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Satsuma Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.25

Short Interest

There is no current short interest data available for STSA.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Satsuma Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Satsuma Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of Satsuma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.26% of the stock of Satsuma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STSA Stock Analysis - Frequently Asked Questions

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) posted its earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.09.

When did Satsuma Pharmaceuticals IPO?

Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Satsuma Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Regional Banks
• Current Symbol: NASDAQ:STSA
• CIK: 891106
• Web: www.satsumarx.com
• Phone: 650-410-3200
• Fax: N/A
• Employees: 21
• Year Founded: 2016

Profitability

• EPS (Most Recent Fiscal Year): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-70,060,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.24%
• Return on Assets: -102.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.44
• Quick Ratio: 7.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 33,150,000
• Free Float: 22,809,000
• Market Cap: $36.47 million
• Optionable: Not Optionable
• Beta: 0.10